Moksha8 Pharmaceuticals, Inc.
Location
Pennsylvania
Founded
2006-03-24
Risk Signals
9 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Moksha8 Pharmaceuticals, Inc.
Live alerts from global media, monitored by Business Radar
2021-06-22 (prnewswire.com)
M8 Pharmaceuticals and UCB partner for Central Nervous System and Respiratory Portfolio in Mexico
/PRNewswire/ -- m8 Pharmaceuticals and UCB Mexico, an affiliate of a global pharmaceutical company, have signed an exclusive promotion and commercialization...
Read more
2010-10-04 (genengnews.com)
Watson Invests $30M in Moksha8 and Forms Marketing Partnership for Brazil and Mexico
Watson may invest another $20 million if Moksha8 acquires more products over the next year.
Read more
(businesskorea.co.kr)
Daewoong Pharmaceutical Secures 180 Bil. Won Nabota Export Deal with Moksha8 -
On Feb. 14, Daewoong Pharmaceutical announced a botulinum toxin Nabota export contract worth 180 billion won with its Brazilian partner, Moksha8. This agreemen
Read more
(prnewswire.com)
M8 Pharmaceuticals and Daewoong Pharmaceutical strengthen their strategic partnership by signing an exclusive licensing agreement for Envlo™ (Enavogliflozin) for Brazil and Mexico
/PRNewswire/ -- M8 Pharmaceuticals and Daewoong Pharmaceuticals announced they have signed an exclusive licensing agreement whereby M8 will have the rights to...
Read more
(prnewswire.com)
Bened Biomedical Grants Exclusive Rights for PS128™ to M8 Pharmaceuticals
/PRNewswire/ -- M8 Pharmaceuticals (formerly moksha8), announced that it has entered into an exclusive licensing agreement with the probiotics company Bened...
Read more